Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
200 participants
INTERVENTIONAL
2024-02-23
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of SGN-STNV in Advanced Solid Tumors
NCT04665921
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
NCT06608940
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
NCT00066612
SLV-154 Treatment of Metastatic Solid Tumors
NCT06771219
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
NCT00006361
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Dose Expansion
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Combination Dose Escalation
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
Dose Expansion for Metastatic Castration Resistant Prostate Cancer
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Dose Expansion for Pancreatic Ductal Adenocarcinoma
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Dose Expansion for Solid Tumors with Brain Metastases
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Evaluable or Measurable disease (RECIST 1.1 Criteria).
* ECOG Performance Status 0 or 1.
* Life expectancy \> 3 months
Exclusion Criteria
* Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
* Significant cardiovascular disease within 6 months
* Significant gastrointestinal disease
* HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load
* Liver dysfunction
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synnovation Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University
New Haven, Connecticut, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
START Center for Cancer Care
West Valley City, Utah, United States
Scientia Clinical Research
Randwick, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Linear Clinical Research
Crawley, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNV1521-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.